1,721,005 research outputs found
Osteosarcopenia in hip fracture: taking cues from pathophysiology for clinical practice
No full text: Hip fractures are common in older and frail adults, and the risk of adverse outcomes and mortality is significantly increased in patients affected by osteosarcopenia. Identifying particularly vulnerable subjects is a critical step to act aimed at promoting postoperative recovery and reducing the risk of adverse events. However, the diagnostic criteria that are currently used to establish the severity of osteosarcopenia are not easily applicable in patients with hip fractures and impaired mobility. In this review, the new knowledge on the pathophysiology of osteosarcopenia that provides several cues for studying biomarkers potentially useful in clinical practice is summarized. Although significant progress has been obtained in understanding the biological mechanisms leading to the involution of the bone- muscle unit, further studies are needed to identify clinically relevant biomarkers and their diagnostic accuracy in establishing the severity of the osteosarcopenia, predicting adverse outcomes, and guiding physicians in choosing appropriate therapeutic interventions
Role of citrate in pathophysiology and medical management of bone diseases
Full text linkCitrate is an intermediate in the “Tricarboxylic Acid Cycle” and is used by all aerobic organisms to produce usable chemical energy. It is a derivative of citric acid, a weak organic acid which can be introduced with diet since it naturally exists in a variety of fruits and vegetables, and can be consumed as a dietary supplement. The close association between this compound and bone was pointed out for the first time by Dickens in 1941, who showed that approximately 90% of the citrate bulk of the human body resides in mineralised tissues. Since then, the number of published articles has increased exponentially, and considerable progress in understanding how citrate is involved in bone metabolism has been made. This review summarises current knowledge regarding the role of citrate in the pathophysiology and medical management of bone disorders
Morphometric dual-energy X-ray absorptiometry (MXA) for identification of vertebral fractures.
No full textCitrate supplementation restores the impaired mineralisation resulting from the acidic microenvironment: An in vitro study
Full text linkChronic metabolic acidosis leads to bone‐remodelling disorders based on excessive mineral matrix resorption and inhibition of bone formation, but also affects the homeostasis of citrate, which is an essential player in maintaining the acid–base balance and in driving the mineralisation process. This study aimed to investigate the impact of acidosis on the osteogenic properties of bone‐forming cells and the effects of citrate supplementation in restoring the osteogenic features impaired by the acidic milieu. For this purpose, human mesenchymal stromal cells were cultured in an osteogenic medium and the extracellular matrix mineralisation was analysed at the micro‐ and nano‐level, both in neutral and acidic conditions and after treatment with calcium citrate and potassium citrate. The acidic milieu significantly decreased the citrate release and hindered the organisation of the extracellular matrix, but the citrate supplementation increased collagen production and, particularly calcium citrate, promoted the mineralisation process. Moreover, the positive effect of citrate supplementation was observed also in the physiological microenvironment. This in vitro study proves that the mineral matrix organisation is influenced by citrate availability in the microenvironment surrounding bone‐forming cells, thus providing a biological basis for using citrate‐based supplements in the management of bone‐remodelling disorders related to chronic low‐grade acidosis
Hypogonadism and reduced bone mineral density in heterozygous H63D mutation in the HFE gene: an unusual presentation of hereditary hemochromatosis.
No full textAsymptomatic primary hyperparathyroidism: surgical and medical management
No full textPrimary hyperparathyroidism (PHPT) is a common endocrine disorder, frequently asymptomatic. Notwithstanding, mild PHPT may cause adverse skeletal effects that include high bone remodeling, reduced bone mineral density (BMD), and increased fracture risk. The definitive therapy for symptomatic and asymptomatic PHPT (aPHPT) is parathyroidectomy, which has been shown to increase BMD. In patients who choose not to be treated surgically or have contraindications for surgery, medical therapy should include drugs designed to protect the skeleton and/or to lower serum calcium, such as bisphosphonates, hormone replacement, and/or calcimimetic agents. However, there are currently no fracture data for any of these options. Obviously, there is the need for larger randomized controlled trials with fractures as end-points to evaluate the efficacy of medical treatment
- …
